Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

BACKGROUND: Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of anthracyclines, but in the USA and some European countries, its use had been restr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganatra, Sarju, Nohria, Anju, Shah, Sachin, Groarke, John D., Sharma, Ajay, Venesy, David, Patten, Richard, Gunturu, Krishna, Zarwan, Corrine, Neilan, Tomas G., Barac, Ana, Hayek, Salim S., Dani, Sourbha, Solanki, Shantanu, Mahmood, Syed Saad, Lipshultz, Steven E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048095/
https://www.ncbi.nlm.nih.gov/pubmed/32154008
http://dx.doi.org/10.1186/s40959-019-0036-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048095/
https://www.ncbi.nlm.nih.gov/pubmed/32154008
http://dx.doi.org/10.1186/s40959-019-0036-7

Ejemplares similares